Evidence map›Paper›PMID 40303406›Full record

SynthesisFrontiers in immunology2025

Ocular markers of microangiopathy and their possible association with cardiovascular risk in patients with systemic inflammatory rheumatic diseases: a systematic review.

Bengta Sturm, Anna-Lena Zang, Julia Stingl, Rebecca Hasseli-Fräbel, Antonis Fanouriakis, Andreas Schwarting, Christian Geber, Julia Weinmann-Menke, Mohammed Alhaddad, Konstantinos Triantafyllias

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bengta Sturm *Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Johannes Gutenberg University Medical Center, Mainz, Germany.
Anna-Lena Zang *Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Johannes Gutenberg University Medical Center, Mainz, Germany.
Julia StinglDepartment of Ophthalmology, Johannes Gutenberg University Medical Center, Mainz, Germany.
Rebecca Hasseli-FräbelCenter for Translational Rheumatology und Immunology, Institute of Musculoskeletal Medicine (IMM), University of Münster, Münster, Germany.
Antonis FanouriakisRheumatology and Immunology Department, Attikon University Hospital, National and Kapodistrian Universitiy of Athens, Athens, Greece.
Andreas SchwartingDepartment of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Johannes Gutenberg University Medical Center, Mainz, Germany.
Christian GeberDRK Schmerz-Zentrum Mainz, Mainz, Germany.
Julia Weinmann-MenkeDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine I, Johannes Gutenberg University Medical Centre, Mainz, Germany.
Mohammed AlhaddadDepartment of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Johannes Gutenberg University Medical Center, Mainz, Germany.
Konstantinos TriantafylliasDepartment of Internal Medicine I, Division of Rheumatology and Clinical Immunology, Johannes Gutenberg University Medical Center, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals with autoimmune rheumatic diseases (ARDs) are at a higher cardiovascular (CV) risk due to systemic inflammation, which contributes to endothelial dysfunction, atherosclerosis, and structural changes in the vessel walls. Along with traditional CV risk factors like dyslipidaemia, arterial hypertension, obesity, and impaired glucose metabolism, these patients have a severe prognosis with higher CV morbidity and mortality rates. To date, there is limited data on the optimal CV screening methods for individuals with ARDs, as conventional risk algorithms may underestimate the influence of chronic inflammation. In comparison to macrovascular assessment methods, such as carotid-femoral pulse wave velocity and carotid sonography, microvascular changes, which may precede macrovascular disease, have been less investigated. The ocular microvasculature reflects systemic vascular health and can reveal early signs of CV disease. Changes in retinal vessels have been linked to an increased long-term risk of CV mortality and ischemic stroke in longitudinal studies of the general population, such as the large Atherosclerosis Risk in Communities (ARIC) study. Additionally, various cross-sectional and follow-up studies in patients with ARDs have demonstrated associations between ocular vessel changes, traditional CV risk scores, and disease-related characteristics, suggesting a potential role for ocular assessments in CV risk screening. In this review work, research from 26 studies retrieved from the PubMed and Web of Science databases has been highlighted. Herein, we evaluate the techniques of retinal vessel analysis (RVA), optical coherence tomography angiography (OCT-A), spectral domain-OCT (SD-OCT), and retrobulbar color Doppler. Specifically, we examine the available data on their associations with key CV risk factors, systemic inflammation, surrogate CV markers, and traditional CV risk scores. Furthermore, we discuss their potential diagnostic value in both ARDs and the general population. Despite current limitations, such as small sample sizes and methodological heterogeneity, initial findings suggest that these techniques may provide valuable insights into microangiopathy and CV risk. Future research should focus on larger, well-designed longitudinal studies to establish their prognostic value and potential integration into clinical practice.

Indexed as

Cardiovascular DiseasesEyeMicrovesselsRheumatic DiseasesBiomarkersHeart Disease Risk FactorsHumansInflammationRetinal VesselsRisk FactorsBiomarkersmicroangiopathyoptical coherence tomography angiography (OCT-A)retinal vessel analysis (RVA)retrobulbar color Dopplerrheumatoid arthritis (RA)spectral domain optical coherence tomography (SD-OCT)systemic lupus erythematosus (SLE)systemic sclerosis (SSc)

Identifiers

PMID40303406
PMCPMC12037583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.